Diagnostic Interpretation of Monoclonal Spike on SPEP with Kappa Light Chain

Introduction to Monoclonal Gammopathies

The presence of a monoclonal spike on SPEP with immunofixation showing kappa light chain indicates a clonal plasma cell or lymphoproliferative disorder producing monoclonal kappa immunoglobulin, requiring immediate evaluation to distinguish between benign conditions, premalignant states, malignant disease, or monoclonal gammopathy of renal significance (MGRS) 1, 2.

The detection of a monoclonal kappa light chain on immunofixation confirms clonality, as normal plasma cells produce both kappa and lambda light chains in a balanced ratio 3.
Clonal proliferation of plasma cells or B-lymphocytes producing exclusively kappa light chains indicates a potential malignancy 4, 3, 1.
An abnormal kappa/lambda free light chain ratio (>1.65) confirms kappa clonality 1, 2.

The National Comprehensive Cancer Network (NCCN) recommends obtaining serum free light chain (FLC) assay, 24-hour urine protein electrophoresis (UPEP), and urine immunofixation (UIFE) to detect Bence Jones proteinuria 5, 6.
Quantitative immunoglobulins (IgG, IgA, IgM) should be performed to identify the heavy chain type 6, 7.

The International Myeloma Society recommends evaluating for myeloma-defining events, including hypercalcemia, renal insufficiency, anemia, and bone lesions 5, 6.
Hypercalcemia is defined as serum calcium >11 mg/dL or >2.75 mmol/L 7, 8.
Renal insufficiency is defined as creatinine >2 mg/dL or creatinine clearance <40 mL/min 5.
Anemia is defined as hemoglobin <10 g/dL or >2 g/dL below normal 5, 7.

Monoclonal Gammopathy of Undetermined Significance (MGUS) is diagnosed when serum monoclonal protein <30 g/L, bone marrow plasma cells <10%, and no CRAB features are present 8, 2.
Smoldering multiple myeloma is diagnosed when serum monoclonal protein ≥30 g/L or bone marrow plasma cells 10-60%, with no CRAB features or myeloma-defining events 5, 8.
Active multiple myeloma is diagnosed when bone marrow plasma cells ≥10% and one or more CRAB criteria are present 5, 6.

The NCCN recommends close monitoring without treatment for smoldering myeloma, unless enrolled in a clinical trial 5.
Immediate treatment with combination chemotherapy is required for active multiple myeloma 5, 6.
Treatment for MGRS is directed at reducing nephrotoxic monoclonal immunoglobulin production 4, 1.

Never rely on SPEP alone, as immunofixation is mandatory to confirm monoclonality and identify the light chain type 5, 6.
Always obtain serum FLC assay, as SPEP can miss up to 25% of MGUS cases and 60% of light chain myeloma cases 6.
Use the same FLC assay for serial monitoring, as results between different assays are not mathematically convertible 3, 1.